Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: The TIGER That Came To Lilly

Executive Summary

The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.

Advertisement

Related Content

Stockwatch: Regeneron Failure Could Hurt Rivals More
Stockwatch: Lilly And GW Move Goalposts
Stockwatch: Oscillating fortunes
Mixed bag? Biogen's aducanumab shows continued dose-correlation
Sunesis sinks on Phase III Qinprezo survival miss
Inspire tumbles as TIGER-2 fails in cystic fibrosis
Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel